Statement of
Carl E. Gulbrandsen
Before the
House Judiciary Subcommittee on
Courts, the Internet and Intellectual Property
On
Patent Law and Non-Profit Research Collaboration
Carl E. Gulbrandsen
Managing Director
PH: 608-263-2824
FAX: 608-263-1064
carl@warf.ws
Carl E. Gulbrandsen
Managing Director
RE: Testimony to the Judiciary Subcommittee on
Courts, the Internet and Intellectual Property Hearing on Patent Law and
Non-Profit Research Collaboration
Mr. Chairman, thank you for the opportunity to testify before your Subcommittee on the important topic of “patent law and non-profit research collaboration.”
My name is Carl E.
Gulbrandsen. I am the Managing Director
of the Wisconsin Alumni Research Foundation, known as WARF. WARF is the patent management organization
for the University of Wisconsin-Madison.
My statement today is being made on behalf of WARF and the Council on
Governmental Relations known as COGR. COGR is an association of 145
research-intensive universities in the
I. Background
WARF was founded in 1925 and is one of the earliest organizations engaged in university technology transfer. WARF exists to support scientific research at the University of Wisconsin-Madison. This mission is carried out by transferring university technology to the marketplace for the benefit of the university, the inventors and the public. Licensing income is returned to the university to fund further scientific research.
Over its 76-year existence, WARF has contributed over $600 million of licensing income to UW-Madison scientific research; but of greater significance is the fact that WARF’s technology transfer successes have had a profound and positive effect upon the welfare, health and safety of humankind. Included among university inventions patented and licensed by WARF are: Professor Harry Steenbock’s Vitamin-D invention which essentially eradicated rickets as a childhood disease; Professor Karl Elvehjem’s copper-iron complexes which improved the physiological assimilation of iron in humans; Professor Karl-Paul Link’s discovery of Coumadin®, the most widely used blood-thinner for treatment of cardiovascular disease, and its counterpart Warfarin, still the most widely used rodenticide world-wide; Professor Charles Mistretta’s digital vascular imaging technology which enabled accurate diagnosis of blockage of the vessels of the heart; Professor Hector DeLuca’s Vitamin-D derivatives which are widely used to treat osteoporosis, renal disease and other diseases; and currently, Professor James Thompson’s human embryonic stem cell lines which have unprecedented potential for research and clinical application of presently untreatable diseases such as Parkinson’s disease and diabetes. In total, the benefit to the public derived from these and other inventions is incalculable.
The success of bringing these and countless university inventions to the marketplace has depended on rich collaborations among scientists within the university; collaborations among scientists at different universities and collaborations among university and industry scientists. Collaboration among scientists in husbanding research dollars makes good sense with the cost and complexity of research today especially with various institutions engaged in essentially the same technological areas. Moreover, the evolution of science has made interdisciplinary research more and more common and, in fact essential, if solutions to complex problems are to be found. A very recent stunning example of this is the sequencing of the human genome.
Collaborative
research among, private, public and non-profit entities is quantifiably
important to the
Public funding of
university research and the encouragement of collaborations among scientists at
public, private and non-profit entities has been a keystone of the
collaborating scientists since most institutions operate under the provisions of law that give the institution the right to retain title to any invention made with federal funds. That is the applicable rule even where the institution is in a sub-contracting situation where the prime contractor is the recipient of federal funds. Thus, in collaboration on an invention, each party may hold ownership rights.
II. University Patent Licensing
University patent licensing as we know
it today has its roots in enactment in 1980 of Pub. L. No. 96-517, the Patent
and Trademark Law Amendments Act, and amendments included in Pub. L. No.
98-628, enacted into law in 1984. See 35 U.S.C. §§ 200-212. This Subcommittee played an instrumental role
in the crafting of a chapter of the Patent Act relating to patent rights in
inventions made with federal assistance (chapter 18) (referred to as the
Bayh-Dole Act), and its cardinal principle that the public benefits from a
policy that permits universities and small businesses to elect ownership of
inventions made under federal funding and to become participants in the
commercialization process. After 1984,
universities and colleges developed and strengthened the internal expertise
needed to engage effectively in the patenting and licensing of inventions. A measure of the success of Bayh-Dole Act is
the growth of the Association of University Technology Managers (“AUTM”) from
113 members in 1979 to over 1800 today.
The Act, so successful in the transfer of university technology to
industry, encourages collaborations between industry and university
scientists. It is well known that
industry depends heavily on collaborations with universities for basic research. In the pharmaceutical, biotech and
hi-technology areas,
III. A Threat to Collaborative Research
In spite of the trend toward scientific collaboration and the economic and practical necessity for such collaborations, a recent decision of the U.S. Court of Appeals for the Federal Circuit threatens to chill such collaborative activity. This decision, which cries for correction, is Oddzon Products, Inc. v. Just Toys, Inc[3]. Oddzon interpreted subsection 103(c) of the Patent Act to hold that prior art under subsections 102 (f) and (g)[4] could be used to determine the obviousness of an invention where:
a. there was no common ownership or assignment of the invention and information being shared among collaborators; and
b. the information exchanged was not publicly known.
That holding made it clear that information under 102 (f) or (g) could invalidate a patent in the circumstances of joint collaborative research. The Oddzon decision has been viewed as creating a significant threat for the loss of intellectual property rights for inventors who engage in joint research and development projects with scientists not employed by the same entity, be it a university or corporation. Thus, while the need for collaborative research in the public interest is becoming more and more evident, the Oddzon decision exerts a substantial chilling effect on collaborative efforts among universities, the private sector and the government.
This
is clearly not what Congress, and this Subcommittee, intended when it amended
section 103(c) in 1984 in the Patent Law Amendments Act of 1984 [5]
in order to encourage open communication among members of research teams
working in corporations, universities or other organizations. See
Remarks of Robert W. Kastenmeier, 129 Cong. Rec. E5777 (daily ed.,
A
bit of legislative and judicial background is in order. The current quandary regarding section 103
had its roots in a decision of the caselaw of the U.S. Court of Customs and
Patent Appeals, the forerunner of the Federal Circuit, which interpreted
section 103 to mean that earlier inventions made by individual members of a research
team would be used under section 103 to preclude the team’s invention from
being patented.[6] This caselaw was a significant concern to entities, both
public and private, that utilize team research.
Seeking reform, they approached this Subcommittee. And the Subcommittee responded,
producing a legislative proposal that was enacted into law. See
P.L. No. 98-622, 98th Cong., 2d Sess. (1984), 98 Stat. 3383. Section 103 was amended by adding the current
subsection 103(c) to address the problem created by the CCPA’s interpretation
related to team research within an organization. The legislative history of the 1984 amendment
clearly establishes that subsection 103(c) was designed to help encourage
teamwork at least within
organizations. Given the text of subsection
103(c) and its legislative history, it is clear that the enactment of
subsection 103(c) sought to encourage teamwork among researchers, rather than
stifle team research. In floor debate,
Rep. Kastenmeier (who served as floor manager) characterized the amendment as
being broader than teamwork “within” organizations, stating that the “change
will be of material benefit to university and corporate research laboratories
where the free exchange of ideas and concepts may have been hampered by the current
state of the law with respect to what constitutes ‘prior art.’” See
130 Cong. Rec. H10522, 10529 (daily ed. ,
However, after the passage of thirteen years, the Oddzon court held that prior art under sections 102(f) or (g) could be used to determine the obviousness of an invention in situations where (a) there was no common ownership or assignment of the invention and information being shared among the collaborators, and (b) the information exchanged was not publicly known. Effectively, the Oddzon decision creates a significant threat for the loss of intellectual property rights for inventors that engage in joint research projects with scientist from a different company or institution.
The solution is a legislative one. The Oddzon court itself invited Congress to review its decision stating that “it is sometimes more important that a close question be settled one way or another than which way it is settled. We settle the issue here (subject of course to any late intervention by Congress …).” 122 F.3d at 1403.
Government-led initiatives to encourage the unhindered flow of information among scientists in the interest of meeting the technological needs of the country and maintain its technological leadership in the world are key elements in the consideration of the present initiative to recognize the adverse impact that the Oddzon decision is having on those broad goals. More immediate to the university sector is the potential loss of invaluable intellectual property rights and the delays or failure to achieve research goals where a collaborative effort would offer an opportunity to efficaciously move ahead.
Chapter 18 of the Patent Act is of great value for universities as it provides retention of title of their intellectual property. Universities are also keenly aware of its objective, which is to utilize the patent system to transfer technology to the private sector for development of the technology in the marketplace. The private sector is fully aware of the Chapter 18 having interfaced with it for over 20 years, and appreciates that it affords a basis for protecting marketplace development and investment efforts. A significant factor in that university-private sector relationship is the willingness and opportunity to define ownership of an invention made jointly by those entities and the disposition of such jointly-owned inventions should the need arise. That opportunity under the proposed legislation should lay to rest voiced concerns about two patents directed to the same subject matter issuing to different parties in the event a collaborative arrangement is dissolved and afford a further spur to greater collaboration between the university and private sectors. This could readily result in more efficient development of products utilizing tax supported research results, and an increase in the transfer of technology for the public good.
Towards this end, we would propose a clarifying amendment to section 103 (c) that would result in:
· increasing the flow of information among scientists at different institutions;
· increasing the collaboration of scientists both within and without a given
institution;
· promoting collaborations between the university and the private sector;
· promoting collaborations between government laboratories and the private sector
as well as with the university sector; and
· enhancing the national pool of knowledge because of the greater unhindered flow
of information among scientists.
The proposed amendment should be
prospective only. Further, the amendment
should not affect any final decision of a court or the Patent & Trademark
Office that is rendered prior to the date of enactment and, should not affect
the right of any party in any case pending before the PTO or a court on the
date of enactment to have rights determined on the basis of the substantive law
prior to the date of enactment.
IV. Related Issues
There
is widespread recognition that the Bayh-Dole Act has been and continues to be
successful beyond all expectations. It is unique in the world and is an
essential component in the
Yet, in spite of its undisputed success, there are continued attempts to alter the statutory framework so as to favor certain industries or groups. I trust that this Committee in its wisdom will safeguard such an important legacy of this committee and oppose any legislation that compromises its demonstrated success.
V. Conclusion
Mr. Chairman, thank you again for your time and attention. In conclusion, I leave you with three recommendations:
· an amendment to the Patent Act is necessary to promote collaborative research amongst the university and non-profit sector, the private sector and the government to achieve the promise of the 1984 amendments of this Subcommittee;
· an amendment which will, prospectively, reverse the holding in the Oddzon decision; and
· protection of Chapter 18 of the Patent Act from amendments that compromise its demonstrated success.
If there are any questions, I will be pleased to answer them.
[1] Calculated on the realized gross license income applying an average of 3% as the royalty charge.
[2] Citing AUTM Licensing Survey 2000,
Association of University Technology Managers, Inc.,
[3] 122 F.3d 1396, 43
[4] Section 103(c) was amended by the American Inventors Protection Act of 1999 to add Section (e) to the 103(c) exclusions.
[5] P.L. No. 98-622, 98th Cong., 2nd Sess. (1984), 98 Stat 3383
[6] See In re Bass, 474 F.2d 1276 (CCPA 1973) and In re Clemens, 622 F.2d 1029 (CCPA 1980).